Key result
Nonmetastatic colorectal cancer survivorship linked to ~57% higher hypertension risk vs controls.
Why the study?
Colorectal cancer survivors often have multiple chronic conditions, prompting the need to assess their likelihood of being diagnosed with cardiovascular disease-related chronic conditions and achieving risk-factor control compared to noncancer controls.
Does nonmetastatic colorectal cancer survivorship increase the risk of cardiovascular disease-related chronic conditions compared to matched noncancer controls?
Case-Control (n=38,824)
Yes
Does nonmetastatic colorectal cancer survivorship increase the risk of cardiovascular disease-related chronic conditions compared to matched noncancer controls?
Nonmetastatic colorectal cancer survivors have a significantly higher likelihood of being diagnosed with hypertension in the year following diagnosis compared to matched noncancer controls, highlighting the need for targeted cardiovascular risk management in this population.
Answers are grounded in this paper and cite their sources.
May warrant closer hypertension monitoring in nonmetastatic CRC survivors; case-control data leaves open causality and detection bias.
PURPOSE: The growing number of colorectal cancer (CRC) survivors often have multiple chronic conditions. Comparing nonmetastatic CRC survivors and matched noncancer controls, our objectives were to determine the odds of CRC survivors being diagnosed with cardiovascular disease (CVD)-related chronic conditions and their likelihood of control during the year after CRC diagnosis. PATIENTS AND METHODS: We retrospectively identified patients diagnosed with nonmetastatic CRC in the Veterans Affairs health care system from fiscal years 2009 to 2012 and matched each with up to 3 noncancer control patients. We used logistic regression to assess differences in the likelihood of being diagnosed with CVD-related chronic conditions and control between nonmetastatic CRC survivors and noncancer controls. RESULTS: We identified 9,758 nonmetastatic CRC patients and matched them to 29,066 noncancer controls. At baseline, 69.4% of CRC survivors and their matched controls were diagnosed with hypertension, 52.4% with hyperlipidemia, and 36.7% with diabetes. Compared to matched noncancer controls, CRC survivors had 57% higher odds of being diagnosed with hypertension (OR=1.57, 95% CI=1.49-1.64) and 7% higher odds of controlled blood pressure (OR=1.07, 95% CI 1.02, 1.13) in the subsequent year. Compared to matched noncancer control patients, CRC survivors had half the odds of being diagnosed with hyperlipidemia (OR=0.50, 95% CI=0.48-0.52) and lower odds of low-density lipoprotein (LDL) control (OR 0.88, 95% CI 0.81-0.94). There were no significant differences between groups for diabetes diagnoses or control. CONCLUSION: Compared to noncancer controls, nonmetastatic CRC survivors have 1) greater likelihood of being diagnosed with hypertension and worse blood pressure control in the year following diagnosis; 2) lower likelihood of being diagnosed with hyperlipidemia or LDL control; and 3) comparable diabetes diagnoses and control. There may be a need for hypertension control interventions targeting cancer survivors.
No takes yet. Share an insight, caveat, or question.
Zullig et al. (2019) conducted a case-control in Nonmetastatic colorectal cancer (n=38,824). Nonmetastatic colorectal cancer vs. Matched noncancer controls was evaluated on Diagnosis of hypertension in the first year following CRC diagnosis (OR 1.57, 95% CI 1.49-1.64, p=<0.0001). Nonmetastatic colorectal cancer survivors had 57% higher odds of being diagnosed with hypertension (OR 1.57) in the year following diagnosis compared to matched noncancer controls.
Synapse has enriched 10 related papers. Consider them for comparative context: